Expert insights. Personalized for you.
Blocked by the White House from issuing new vaccine guidelines, the FDA made its criteria for an emergency authorization clear anyway, publishing requirements it had previously communicated to drugmakers MORE
With multiple COVID-19 vaccines in development, the CDC is confident that any vaccines the FDA authorizes or approves will be safe because they are based on the FDA’s usual stringent protocols. The greater question, after a vaccine is approved, is how it will be distributed MORE
have aggressively signed preorder deals with vaccine developers. Both the U.S. and U.K. An agreement with AstraZeneca is the EU's first MORE
Catalent, which is already helping the British pharma make its vaccine, will now add key services from a Maryland gene therapy plant MORE
companies, the Russian vaccine could be used broadly because it doesn't need to be kept frozen While the shot appeared less potent than those being advanced by U.S. and U.K. MORE
The FDA has suspended the planned start of a late-stage trial of Inovio's experimental shot, dealing another setback to one of the most advanced DNA-based vaccine programs in development MORE
Both companies believe the messenger RNA technology they're using in their coronavirus vaccines could be applied to create a better flu shot MORE
Normally staid affairs, next Thursday's advisory committee meeting could be historic and set expectations for how the FDA will approach any future vaccine approval MORE
Initial vaccine supplies will be limited. Advisory groups, most recently that of the National Academies, are developing plans to figure out who should get access first MORE
The two vaccine developers are betting their proven technology will lead to a more potent shot than others, making up for their slower pace of testing MORE
HHS Secretary Alex Azar said six vaccine developers involved with Operation Warp Speed had begun commercial manufacturing of their experimental shots MORE
The reported talks between CanSino and several countries highlight the urgency with which governments are operating to secure supply of experimental coronavirus vaccines MORE
In an unusual letter, the heads of nine top vaccine developers pledged to "stand with science" and only move forward with approval applications if warranted by clinical results MORE
But J&J is now the second vaccine developer, along with AstraZeneca, to suspend testing for a safety review The company did not disclose details, nor could it confirm whether the participant had received its shot. MORE
QUICK READ: As COVID-19 vaccines enter Phase III trials one has to wonder just how transparent pharma companies will be with the data. The rush to develop a COVID-19 vaccine is well underway because there are billions of dollars in profits at stake. As I See It COVID Vaccine MORE
QUICK READ : Pharma had a chance to earn some goodwill with a very skeptical public but it’s become obvious that the rush to develop a vaccine is about profit, executive stock, and Wall Street despite potential huge investments from the government. in the news COVID Vaccine MORE
An initial look at the vaccine's effects on the elderly shows those in their 70s had similar responses to those under 55, Moderna told a government panel MORE
has already invested heavily in Moderna's vaccine, having previously committed $1 billion to fund clinical trials and manufacturing scale-up The U.S. MORE
QUICK READ : The government is agreeing to pay billions of dollars to the first company that developed a COVID-19 vaccine. billion for 100 million doses of a vaccine made by Pfizer Inc. The question that the media is asking is “will consumers trust a COVID-19 vaccine?” MORE
The CDC, for example, doesn't support vaccine mandates for healthcare workers or essential employees, an agency official told experts convened by the FDA Thursday MORE
These differences also explain why vaccines are necessary for both the flu and COVID-19. Read more Flu Vaccine vs. COVID-19 Vaccine. The post Flu Vaccine vs. COVID-19 Vaccine appeared first on MyLocalStudy.com. MORE
The biotech, a frontrunner in the coronavirus vaccine race, said it won't tie up resources defending the intellectual property covering its experimental shot as long as the pandemic continues MORE
The Arena International Vaccines Virtual Conference on August 12th, 2020 will allow attendees to connect with global leaders in the pharmaceutical industry to discuss the impact of COVID-19 and how to accelerate vaccine trials. Events Featured Events vaccine MORE
Canada was set to help CanSino produce its experimental shot as part of a deal to run what would've been the country's first coronavirus vaccine study MORE
Credit: Stefan Zimmerman Women vaccinated against HPV have a significantly lower risk of developing cervical cancer, and the positive effect is most pronounced for women vaccinated at a young age. MORE
Is a century-old vaccine a ‘game-changer’ for COVID-19? This is especially true in the search for effective therapies to fight COVID-19, and a vaccine. In a worst-case scenario, misplaced hype could lead to a sudden rush to buy doses of the BCG vaccine. MORE
The biotech, among the furthest along in coronavirus vaccine development, is the first developer to share the so-called study protocol of its large Phase 3 trial MORE
The shot, developed by the state-backed Gamaleya Research Institute, hasn't yet been tested in the large, placebo-controlled tests scientists emphasize are needed to prove a vaccine is protective MORE
A participant in a clinical trial of the experimental shot suffered from an unexplained illness, triggering an investigation and a pause in vaccinations MORE
Pfizer, Sanofi, GSK and Merck each reported lower vaccine sales as stay-at-home orders kept people from their regular vaccinations MORE
An emergency clearance is expected for the first vaccine proven effective. But early availability of a shot could jeopardize ongoing studies, and may make tests of other candidates more difficult MORE
Moderna has said that its coronavirus vaccine stimulated an immune response in older people in phase 1 trials, suggesting that the jab is effective in the age groups most susceptible to COVID-19. The US has also bought 100 million doses of the mRNA vaccine for more than $1.5 MORE
The co-leader of an NIH network of coronavirus prevention studies spoke with BioPharma Dive about the FDA's big vaccine meeting this week and what will come next MORE
study participant led to a worldwide pause in vaccinations, the country's drugs regulator and an independent committee allowed testing to resume Six days after a worrisome illness in a U.K. MORE
Credit: WEI Wei Exploration of new leukemia antigens and construction of appropriate delivery systems using FDA-approved material are important strategies for developing leukemia vaccines for clinic use. Medicine & Health Medicine/Health Vaccines MORE
As development towards a COVID-19 vaccine continue so do the number of people who have said they won’t get vaccinated. The only way to get people on board with a vaccination is complete transparency about the product yet both J&J and Pfizer remain silent. MORE
Importantly, the study committee hasn't had reason to pause vaccinations in the trial, something AstraZeneca and the University of Oxford recently reported in tests of their vaccine MORE
Primes company to submit vaccine candidate for rolling review MORE
The decision by European regulators to start speedy, "rolling" reviews of two vaccine candidates comes as the FDA and White House have reportedly been unable to agree on early approval standards MORE
A team at the George Washington University Vaccine Research Unit has developed a controlled human hookworm infection model, accelerating the development of human hookworm vaccines WASHINGTON (August 26, 2020) – A team led by researchers at the George Washington University (GW) has established a controlled human hookworm infection (CHHI) model to accelerate the development of […]. MORE
The Serum Institute of India, a go-to partner for coronavirus vaccine makers, will help Novavax boost capacity to levels matching its larger rivals MORE
Vaccination Related Topics My Local Study
OCTOBER 1, 2020
These differences also explain why vaccines are necessary for both the flu and COVID-19. Read more Flu Vaccine vs. COVID-19 Vaccine. The post Flu Vaccine vs. COVID-19 Vaccine appeared first on MyLocalStudy.com.
World of DTC Marketing
JULY 22, 2020
QUICK READ : The government is agreeing to pay billions of dollars to the first company that developed a COVID-19 vaccine. billion for 100 million doses of a vaccine made by Pfizer Inc. The question that the media is asking is “will consumers trust a COVID-19 vaccine?”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
JULY 28, 2020
QUICK READ : Pharma had a chance to earn some goodwill with a very skeptical public but it’s become obvious that the rush to develop a vaccine is about profit, executive stock, and Wall Street despite potential huge investments from the government. in the news COVID Vaccine
Bio Pharma Dive
OCTOBER 16, 2020
Normally staid affairs, next Thursday's advisory committee meeting could be historic and set expectations for how the FDA will approach any future vaccine approval
World of DTC Marketing
AUGUST 3, 2020
QUICK READ: As COVID-19 vaccines enter Phase III trials one has to wonder just how transparent pharma companies will be with the data. The rush to develop a COVID-19 vaccine is well underway because there are billions of dollars in profits at stake. As I See It COVID Vaccine
Bio Pharma Dive
SEPTEMBER 12, 2020
study participant led to a worldwide pause in vaccinations, the country's drugs regulator and an independent committee allowed testing to resume Six days after a worrisome illness in a U.K.
Bio Pharma Dive
SEPTEMBER 15, 2020
Importantly, the study committee hasn't had reason to pause vaccinations in the trial, something AstraZeneca and the University of Oxford recently reported in tests of their vaccine
Bio Pharma Dive
AUGUST 27, 2020
Canada was set to help CanSino produce its experimental shot as part of a deal to run what would've been the country's first coronavirus vaccine study
Bio Pharma Dive
OCTOBER 22, 2020
The CDC, for example, doesn't support vaccine mandates for healthcare workers or essential employees, an agency official told experts convened by the FDA Thursday
Bio Pharma Dive
JULY 31, 2020
Pfizer, Sanofi, GSK and Merck each reported lower vaccine sales as stay-at-home orders kept people from their regular vaccinations
Bio Pharma Dive
OCTOBER 20, 2020
The co-leader of an NIH network of coronavirus prevention studies spoke with BioPharma Dive about the FDA's big vaccine meeting this week and what will come next
Bio Pharma Dive
SEPTEMBER 17, 2020
The biotech, among the furthest along in coronavirus vaccine development, is the first developer to share the so-called study protocol of its large Phase 3 trial
Bio Pharma Dive
SEPTEMBER 8, 2020
A participant in a clinical trial of the experimental shot suffered from an unexplained illness, triggering an investigation and a pause in vaccinations
Pharma Phorum
OCTOBER 23, 2020
Is a century-old vaccine a ‘game-changer’ for COVID-19? This is especially true in the search for effective therapies to fight COVID-19, and a vaccine. In a worst-case scenario, misplaced hype could lead to a sudden rush to buy doses of the BCG vaccine.
Bio Pharma Dive
AUGUST 26, 2020
An initial look at the vaccine's effects on the elderly shows those in their 70s had similar responses to those under 55, Moderna told a government panel
Bio Pharma Dive
SEPTEMBER 28, 2020
The FDA has suspended the planned start of a late-stage trial of Inovio's experimental shot, dealing another setback to one of the most advanced DNA-based vaccine programs in development
Bio Pharma Dive
OCTOBER 8, 2020
The biotech, a frontrunner in the coronavirus vaccine race, said it won't tie up resources defending the intellectual property covering its experimental shot as long as the pandemic continues
Bio Pharma Dive
AUGUST 11, 2020
The shot, developed by the state-backed Gamaleya Research Institute, hasn't yet been tested in the large, placebo-controlled tests scientists emphasize are needed to prove a vaccine is protective
ERT
AUGUST 3, 2020
The Arena International Vaccines Virtual Conference on August 12th, 2020 will allow attendees to connect with global leaders in the pharmaceutical industry to discuss the impact of COVID-19 and how to accelerate vaccine trials. Events Featured Events vaccine
Scienmag
SEPTEMBER 30, 2020
Credit: Stefan Zimmerman Women vaccinated against HPV have a significantly lower risk of developing cervical cancer, and the positive effect is most pronounced for women vaccinated at a young age.
Bio Pharma Dive
OCTOBER 6, 2020
Blocked by the White House from issuing new vaccine guidelines, the FDA made its criteria for an emergency authorization clear anyway, publishing requirements it had previously communicated to drugmakers
Bio Pharma Dive
AUGUST 28, 2020
The reported talks between CanSino and several countries highlight the urgency with which governments are operating to secure supply of experimental coronavirus vaccines
Bio Pharma Dive
SEPTEMBER 15, 2020
The Serum Institute of India, a go-to partner for coronavirus vaccine makers, will help Novavax boost capacity to levels matching its larger rivals
Scienmag
OCTOBER 12, 2020
Credit: WEI Wei Exploration of new leukemia antigens and construction of appropriate delivery systems using FDA-approved material are important strategies for developing leukemia vaccines for clinic use. Medicine & Health Medicine/Health Vaccines
Bio Pharma Dive
SEPTEMBER 1, 2020
Initial vaccine supplies will be limited. Advisory groups, most recently that of the National Academies, are developing plans to figure out who should get access first
Bio Pharma Dive
OCTOBER 23, 2020
An emergency clearance is expected for the first vaccine proven effective. But early availability of a shot could jeopardize ongoing studies, and may make tests of other candidates more difficult
BioSpace
OCTOBER 13, 2020
With multiple COVID-19 vaccines in development, the CDC is confident that any vaccines the FDA authorizes or approves will be safe because they are based on the FDA’s usual stringent protocols. The greater question, after a vaccine is approved, is how it will be distributed
Bio Pharma Dive
AUGUST 11, 2020
has already invested heavily in Moderna's vaccine, having previously committed $1 billion to fund clinical trials and manufacturing scale-up The U.S.
Bio Pharma Dive
SEPTEMBER 8, 2020
In an unusual letter, the heads of nine top vaccine developers pledged to "stand with science" and only move forward with approval applications if warranted by clinical results
World of DTC Marketing
OCTOBER 20, 2020
As development towards a COVID-19 vaccine continue so do the number of people who have said they won’t get vaccinated. The only way to get people on board with a vaccination is complete transparency about the product yet both J&J and Pfizer remain silent.
Bio Pharma Dive
AUGUST 26, 2020
Catalent, which is already helping the British pharma make its vaccine, will now add key services from a Maryland gene therapy plant
Bio Pharma Dive
SEPTEMBER 17, 2020
Both companies believe the messenger RNA technology they're using in their coronavirus vaccines could be applied to create a better flu shot
Bio Pharma Dive
OCTOBER 6, 2020
The decision by European regulators to start speedy, "rolling" reviews of two vaccine candidates comes as the FDA and White House have reportedly been unable to agree on early approval standards
Bio Pharma Dive
SEPTEMBER 3, 2020
The two vaccine developers are betting their proven technology will lead to a more potent shot than others, making up for their slower pace of testing
Bio Pharma Dive
SEPTEMBER 4, 2020
companies, the Russian vaccine could be used broadly because it doesn't need to be kept frozen While the shot appeared less potent than those being advanced by U.S. and U.K.
Bio Pharma Dive
SEPTEMBER 24, 2020
HHS Secretary Alex Azar said six vaccine developers involved with Operation Warp Speed had begun commercial manufacturing of their experimental shots
Pharma Phorum
AUGUST 27, 2020
Moderna has said that its coronavirus vaccine stimulated an immune response in older people in phase 1 trials, suggesting that the jab is effective in the age groups most susceptible to COVID-19. The US has also bought 100 million doses of the mRNA vaccine for more than $1.5
Bio Pharma Dive
AUGUST 14, 2020
have aggressively signed preorder deals with vaccine developers. Both the U.S. and U.K. An agreement with AstraZeneca is the EU's first
Scienmag
SEPTEMBER 3, 2020
A team at the George Washington University Vaccine Research Unit has developed a controlled human hookworm infection model, accelerating the development of human hookworm vaccines WASHINGTON (August 26, 2020) – A team led by researchers at the George Washington University (GW) has established a controlled human hookworm infection (CHHI) model to accelerate the development of […].
Pharma Times
OCTOBER 15, 2020
Primes company to submit vaccine candidate for rolling review
215 
Let's personalize your content